The Infectious Diseases Clinical Research Consortium has begun enrolling up to 1,000 pregnant and postpartum individuals who have or will receive COVID-19 vaccine in a study to assess vaccine safety, immune response and transfer of antibodies to their infants, the National Institutes of Health announced yesterday. The study will enroll individuals up to two months postpartum, and follow participants and their infants through the first year after delivery.

“Tens of thousands of pregnant and breastfeeding people in the United States have chosen to receive the COVID-19 vaccines available under emergency use authorization,” said Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases “However, we lack robust, prospective clinical data on vaccination in these populations. The results of this study will fill gaps in our knowledge and help inform policy recommendations and personal decision-making on COVID-19 vaccination during pregnancy and in the postpartum period.”
 

Related News Articles

Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Eilidh Pederson, CEO at Western Wisconsin Health, shares lessons from her unique birthing experience — in which she delivered her own baby — and outlines how…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…